REFRACTORY THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to reboot radioactive iodine in stubborn thyroid cancers
Disease control OngoingThis phase 2 trial tests whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has returned or spread and no longer responds to RAI alone. About 34 adults with specific genetic types of thyroid cancer will receive tr…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Targeted drug tipifarnib tested in kids with rare HRAS-Driven cancers
Disease control OngoingThis study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…
Matched conditions: REFRACTORY THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC